NR3C1 and breast cancer: So far, GR signaling has been implicated in the biology of various hematological malignancies as well as solid cancers including lung cancer, prostate cancer, breast cancer, pancreatic cancer, ovarian cancer, endometrial cancer, bladder cancer, colon cancer, liver cancer, and brain cancer [4].